Semaglutide for osteoarthritis

Areas affected by osteoarthritis

A recent study published in the New England Journal of Medicine on October 31, 2024, highlights that once-weekly semaglutide significantly reduces body weight and alleviates pain related to knee osteoarthritis in individuals with obesity, compared to a placebo.

Study Overview

Error creating thumbnail:

Ozempic, a form of semaglutide

The study, led by Henning Bliddal, M.D., from Copenhagen University Hospital at Bispebjerg and Frederiksberg in Denmark, was conducted over 68 weeks at 61 sites across 11 countries. A total of 407 participants with obesity and clinically confirmed moderate knee osteoarthritis characterized by moderate to severe pain were enrolled. Participants were randomly assigned in a 2:1 ratio to receive either once-weekly subcutaneous semaglutide or a placebo, in addition to counseling on physical activity and a reduced-calorie diet.

Key Findings

The study results demonstrated the following:

• Body Weight Reduction: By week 68, participants receiving semaglutide experienced a mean body weight reduction of −13.7%, compared to −3.2% in the placebo group.
• Pain Reduction: The mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score was −41.7 points for the semaglutide group, compared to −27.5 points for the placebo group.
• Improvement in Physical Function: The 36-Item Short Form Health Survey (SF-36) indicated greater improvement in physical function among the semaglutide group, with a mean increase of 12.0 points compared to 6.5 points in the placebo group.

The incidence of serious adverse events was similar between the two groups, indicating that semaglutide was well-tolerated.

References

• NEJM study - Semaglutide for Osteoarthritis

Semaglutide for osteoarthritis Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

Transform Your Life with W8MD Weight Loss Centers

W8MD offers a physician-supervised weight loss program at various locations including New York, Pennsylvania and New Jersey. Our centers provide expert medical guidance, accept most insurances, and offer telemedicine options for convenience.

Why choose W8MD?

• Comprehensive care with FDA-approved medications including:
• Weight loss injections both generic and brand names:
  • Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
• Weight loss medications including Phentermine, Qsymia, Contrave, Diethylpropion etc.
• Accept most insurances for visits or discounted self pay cost.
• Generic weight loss injections starting from just $125.00 for the starting dose
• In person weight loss NYC and telemedicine medical weight loss options in New York city available

Book Your Appointment

Start your weight loss journey today at our centers in New York, and Pennsylvania and visit W8MD.com Call (718)946-5500 for NY and 215 676 2334 for PA